Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
Category: drug costs
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.
Why Does Insulin Cost So Much? Big Pharma Isn’t the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
March Medicaid Madness
With Medicare and Social Security apparently off the table for federal budget cuts, the focus has turned to Medicaid, the federal-state health program for those with low incomes. President Joe Biden has made it clear he wants to protect the program, along with the Affordable Care Act, but Republicans will likely propose cuts to both […]
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
California’s Massive Medicaid Program Works for Some, but Fails Many Others
Medi-Cal serves more than one-third of the state’s population — offering a dizzying range of care to a diverse population. In the new “Faces of Medi-Cal” series, California Healthline will assess the program’s strengths and weaknesses through the lives and experiences of its enrollees.
After Capping the Price of Insulin, Colorado Sets Its Sights on EpiPens
Colorado’s proposed legislation to cap the copay for the EpiPen is part of a nationwide trend as more states try to shield patients from skyrocketing drug prices.
A Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
Mark Cuban Has Been Taking On the Drug Industry. But Which One?
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
